NCT01934634 - Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2016

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

LCL161

LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days

DRUG

Gemcitabine

Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days

DRUG

nab-Paclitaxel

nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days

Trial Locations (1)

2 Sites, Incl Tyler, TX and Dallas, TX